Orcd.Ns
ORCD.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. ORCD.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ORCD.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
ORCD.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.14, indicating a low reliance on debt financing. The company's liquidity position is strong, as evidenced by a current ratio of 2.83 and cash and equivalents of INR 1.8 billion. However, the company reported negative free cash flow of INR -198 million, driven by capital expenditures of INR -1.5 billion, which may signal ongoing investment in infrastructure or R&D.
Profitability metrics for ORCD.NS show a return on equity (ROE) of 7.86% and a return on assets (ROA) of 5.9%, both of which are in line with typical performance for the pharmaceutical industry. The company's net income of INR 996.6 million and operating income of INR 826.5 million reflect a healthy margin structure, although gross profit of INR 2.93 billion suggests moderate cost control.
Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of segment-specific breakdowns implies that the company may operate as a single business unit or that its operations are not publicly segmented. This could limit the ability to assess exposure to specific therapeutic areas or geographic markets.
The company's growth trajectory appears stable, with no immediate signs of significant revenue acceleration or contraction. Analysts have assigned a mean price target of INR 951.50, with a strong buy recommendation from two analysts, suggesting a generally positive outlook. However, the lack of detailed revenue history prevents a more granular assessment of growth trends.
Risk factors for ORCD.NS are currently low, with no immediate liquidity or dilution concerns identified. The company's low debt load and strong equity position reduce financial risk, and there are no signs of near-term dilution from share issuance or convertible instruments. However, the pharmaceutical industry is inherently subject to regulatory and R&D risks, which are not explicitly quantified in the available data.
Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or strategy. The absence of recent earnings call transcripts or 10-K filings in the data set limits the ability to assess management commentary or strategic direction.
- ORCD.NS maintains a strong liquidity position with a current ratio of 2.83 and INR 1.8 billion in cash and equivalents.
- The company's profitability is moderate, with ROE and ROA of 7.86% and 5.9%, respectively.
- Free cash flow is negative due to significant capital expenditures, suggesting ongoing investment.
- Analysts have a generally positive outlook, with a mean price target of INR 951.50 and two strong buy ratings.
- No immediate liquidity or dilution risks are present, and the company's debt-to-equity ratio is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,30 |
| Revenue | —no estimate | —no estimate | 8,0B INR |
| Operating income | —no estimate | —no estimate | -140,0M INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ORCD.NS Market data — financials · 2026-05-28
- Orchid Pharma Ltd Market data — analyst estimates · 2026-05-28